Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

RVT-602

- PMLiVE

Pfizer hits accelerator on Xtandi trial in early prostate cancer

US pharma giant expects PROSPER trial results later this year

- PMLiVE

Practice-changing data for J&J’s Zytiga in prostate cancer

LATITUDE study shows combined drug therapy reduces death risk by 38%

- PMLiVE

J&J aiming for above-average growth thanks to stream of blockbusters

US firm enters highly productive R&D phase

- PMLiVE

Takeda’s gamble on Ariad pays off with Alunbrig approval

ALK-inhibitor will treat NSCLC patients as second-line therapy

- PMLiVE

Japanese pharma pulls no punches with post-Brexit UK

Firm want reassurance from the UK on its future in science and innovation

Using service design to improve patients’ quality of life

Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.

Blue Latitude Health

- PMLiVE

Caring for prostate cancer patients

Although not without its challenges, the appropriate care and support available to patients with prostate cancer is gradually evolving. It’s important not to overlook the all too often ‘unsung heroes’...

Blue Latitude Health

Takeda pilots Apple Watch depression app

Partners with Cognition Kit on patient monitoring wearable

Women’s health in emerging markets

Why can understanding and improving women’s health in emerging markets be challenging? What strategies can global pharma develop to support women and overcome these challenges? Associate Director Rachel Howard and...

Research Partnership

AstraZeneca AZ

AZ agrees to $320m deal for Zoladex

TerSera Therapeutics acquires rights to oncology drug in US and Canada

- PMLiVE

TiGenix cell therapy for Crohn’s fistulas shows long-term benefit

Phase III data for the Takeda-partnered drug raises hopes for upcoming EU approval

- PMLiVE

Takeda UK & Ireland appoints market access director

Peter Wheatley Price brings experience from GSK, Janssen and Boehringer Ingelheim

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links